XRF Scientific (XRF) H1 2026 earnings summary

Executive summary

• Revenue for the half-year ended 31 December 2025 was $31.3 million, up from $28.7 million year-over-year.

• Net profit after tax attributable to equity holders was $5.26 million, compared to $5.01 million in the prior year.

• Total comprehensive income attributable to equity holders was $5.07 million, down from $5.28 million year-over-year due to negative foreign currency translation differences.

Financial highlights

• Gross profit increased to $15.03 million from $13.48 million year-over-year.

• Basic and diluted EPS were 3.7 cents per share, up from 3.6 cents per share year-over-year.

• Cash and cash equivalents at period end were $12.07 million, slightly down from $12.23 million at 30 June 2025.

• Dividends paid during the half-year totaled $6.40 million, up from $5.44 million in the prior year.

Outlook and guidance

• No material events after the reporting date are expected to affect future operations or financial position.